NFA
AXSM icon

Nationwide Fund Advisors’s Axsome Therapeutics AXSM Stock Holding History

Nationwide Fund Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-6,474
Closed -$25K – 3206
2017
Q1 		$25K Hold
6,474
– – ﹤0.01% 3070
2016
Q4 		$44K Hold
6,474
– – ﹤0.01% 3023
2016
Q3 		$51K Hold
6,474
– – ﹤0.01% 3042
2016
Q2 		$49K Buy
+6,474
New +$59.6K ﹤0.01% 3076

Other funds holding AXSM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return

Nationwide Fund Advisors's AXSM Position: Q2 2017 in Review

Nationwide Fund Advisors sold out of Axsome Therapeutics (AXSM) in Q2 2017, closing a stake of 6,474 shares — an estimated $25K sold.

Nationwide Fund Advisors first reported a position in AXSM in Q2 2016 and held it in 4 quarters. The position peaked at $51K in Q3 2016. 35 funds tracked by Wall St. Rank hold AXSM as of Q2 2017.

  • Nationwide Fund Advisors reported no remaining Axsome Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 6,474 Axsome Therapeutics shares in Q2 2017, an estimated $25K.
  • Nationwide Fund Advisors first reported a position in Axsome Therapeutics in Q2 2016 and held it in 4 quarters.
  • Nationwide Fund Advisors's Axsome Therapeutics position peaked at $51K in Q3 2016.
  • 35 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2017.

Based on Nationwide Fund Advisors's 13F filing for Q2 2017, filed 10 Aug 2017.